<qa>  What is the starting dose of L-NMMA?This is a Phase IbII study assessing the maximum tolerated dose MTD, dose-limiting toxicities DLTs, recommended Phase 2 dose RP2D, and efficacy of L-NMMA when combined with docetaxel in refractory locally advanced or metastatic triple negative breast cancer patients. The Phase Ib portion of the study is designed to investigate the combination at two dose levels of docetaxel 75 and 100 mgm2 and 6 dose levels of L-NMMA 5, 7.5, 10, 12.5, 15, and 17.5 mgkg. The starting dose of L-NMMA will be 7.5 mgkg. L-NMMA dose will escalatede-escalate based on DLT occurrence. For the 5, 7.5, 10, 12.5, and 15 mgkg L-NMMA dose levels, docetaxel will be administered at 75 mgm2. For the 17.5 mgkg L-NMMA dose level, docetaxel will be administered at 100 mgm2. In the Phase II portion of the study, the starting dose will be the RP2D determined in the Phase Ib portion of the study. Patients will receive up to 6 21-day cycles of the L-NMMA and docetaxel combination. L-NMMA will be administered via 2-hour intravenous IV infusion on Days 1-5 of each cycle. Docetaxel will be administered via 1-hour IV infusion approximately 15 minutes after the Day 1 L-NMMA infusion. For L-NMMA-induced hypertension, amlodipine 10 mg will be orally administered for 6 days at each cycle. Amlodipine administration will start 24 hours before the first dose of L-NMMA. For docetaxel-induced leukopenia, pegfilgrastim 6 mg will be administered via subcutaneous injection approximately 24 hours after every dose of docetaxel. 